J9181 is terminated (historical record)
Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J9181
10 MG
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 100 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Clinical: Society Comment |
| Facility outpatient hospital services | 100 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Clinical: Society Comment |
| DME supplier services | 11 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Most recent Medicare Part B payment limit · Q3 2026
$1.018per 10 MG
Effective Jul 1, 2026 – Sep 30, 2026 · ASP methodology (per CMS file) · based on Q1 2026 ASP data · coinsurance 20.000%
Not in the latest payment limit file (Q4 2026). Shown for history only.
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $1.018 | 10 MG | 20% | +13.1% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.900 | 10 MG | 20% | −13.8% |
Medicare hospital outpatient (OPPS)
No authoritative public data was located for this field.
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
No CMS NDC–HCPCS crosswalk rows were located. CMS notes its crosswalks are not a comprehensive list of all NDCs.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 16729-0114-08 | EtoposideAccord Healthcare Inc | 25 × 1 | 50 | 50 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 16729-0114-11 | EtoposideAccord Healthcare Inc | 50 × 1 | 100 | 100 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 16729-0114-31 | EtoposideAccord Healthcare Inc | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 16729-0262-31 | EtoposideACCORD HEALTHCARE INC. | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingEtoposide |
| 68001-0682-26 | EtoposideBluepoint Laboratories | 25 × 1 | 50 | 50 | ASP | Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 68001-0683-27 | EtoposideBluepoint Laboratories | 50 × 1 | 100 | 100 | ASP | Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 68001-0265-25 | EtoposideBluePoint Laboratories | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 68001-0265-26 | EtoposideBluePoint Laboratories | 25 × 1 | 50 | 50 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 68001-0265-27 | EtoposideBluePoint Laboratories | 50 × 1 | 100 | 100 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 00015-3404-20 | EtopophosBRISTOL-MYERS SQUIBB COMPANY | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingEtopophos |
| 63323-0104-05 | EtoposideFreseniUS Kabi USA, LLC | 5 × 10 | 10 | 100 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 63323-0104-06 | EtoposideFreseniUS Kabi USA, LLC | 5 × 1 | 10 | 10 | ASP | Q4 2024 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 63323-0104-25 | EtoposideFreseniUS Kabi USA, LLC | 25 × 1 | 50 | 50 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 63323-0104-50 | EtoposideFreseniUS Kabi USA, LLC | 50 × 1 | 100 | 100 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 61269-0410-20 | EtopophosH2 Pharma LLC | 1 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtopophos |
| 00143-9376-01 | EtoposideHikma Pharmaceuticals USA Inc. | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 00143-9510-01 | EtoposideHikma Pharmaceuticals USA Inc. | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 00143-9511-01 | EtoposideHikma Pharmaceuticals USA Inc. | 25 × 1 | 50 | 50 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 00143-9512-01 | EtoposideHikma Pharmaceuticals USA Inc. | 50 × 1 | 100 | 100 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 71288-0175-05 | EtoposideMeitheal Pharmaceuticals Inc. | 5 × 1 | 10 | 10 | ASP | Q1 2026 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 71288-0176-25 | EtoposideMeitheal Pharmaceuticals Inc. | 25 × 1 | 50 | 50 | ASP | Q1 2026 – Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 71288-0177-50 | EtoposideMeitheal Pharmaceuticals Inc. | 50 × 1 | 100 | 100 | ASP | Q3 2026Not in Q4 2026 file | ListedEtoposide |
| 00703-5653-01 | EtoposideSICOR PHARMACEUTICALS, INC. | 5 × 1 | 10 | 10 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingToposar |
| 00703-5657-01 | EtoposideSICOR PHARMACEUTICALS, INC. | 50 × 1 | 100 | 100 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingDoxorubicin Hydrochloride |
| 00703-5656-01 | EtoposideTeva Parenteral Medicines, Inc. | 25 × 1 | 50 | 50 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | Excluded listingDoxorubicin Hydrochloride |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q4 2026 | Termination date set | D — Discontinued | Termination date Sep 30, 2026 |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1987 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Prescribing Information |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $1.044 | 10 MG | 20% | +10.9% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.941 | 10 MG | 20% | −27.8% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.303 | 10 MG | 20% | +22.1% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.067 | 10 MG | 20% | +9.3% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.976 | 10 MG | 20% | −28.9% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $1.373 | 10 MG | 20% | +21.4% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $1.131 | 10 MG | 20% | +8.1% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $1.046 | 10 MG | 20% | +5.3% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $0.993 | 10 MG | 20% | +29.6% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.766 | 10 MG | 20% | +8.8% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $0.704 | 10 MG | 20% | −18.5% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $0.864 | 10 MG | 20% | −3.4% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $0.894 | 10 MG | — | +6.3% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $0.841 | 10 MG | — | +4.7% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.803 | 10 MG | — | +4.7% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $0.767 | 10 MG | — | +1.2% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.758 | 10 MG | — | −4.7% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.795 | 10 MG | — | +11.8% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $0.711 | 10 MG | — | −0.8% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $0.717 | 10 MG | — | −3.6% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $0.744 | 10 MG | — | — | — |
|---|